{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:25:01Z","timestamp":1792081501786,"version":"4.4.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/010.101.009\/2018"],"award-info":[{"award-number":["E-26\/010.101.009\/2018"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40262-023-01291-x","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T06:03:48Z","timestamp":1691647428000},"page":"1219-1230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9441-3938","authenticated-orcid":false,"given":"Thain\u00e1","family":"Toledo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4292-6648","authenticated-orcid":false,"given":"Thales","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-9038","authenticated-orcid":false,"given":"Vanessa G.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-3165","authenticated-orcid":false,"given":"Valdilea Gon\u00e7alves","family":"Veloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-5155","authenticated-orcid":false,"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5230-0003","authenticated-orcid":false,"given":"Sandra Wagner","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2557-601X","authenticated-orcid":false,"given":"Thiago S.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5653-1690","authenticated-orcid":false,"given":"Rita","family":"Estrela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"1291_CR1","doi-asserted-by":"crossref","unstructured":"Aguiar RB, Leal MCC, Marques AP de O, Torres KMS, Tavares MTDB. Idosos vivendo com HIV\u2014comportamento e conhecimento sobre sexualidade: revis\u00e3o integrativa. Ci\u00eanc Sa\u00fade Coletiva. 2020;25:575\u201384.","DOI":"10.1590\/1413-81232020252.12052018"},{"key":"1291_CR2","unstructured":"HIVinfo. FDA Approval of HIV Medicines - A timeline with all the FDA approval dates for HIV medicines, categorized by drug class. 2022. https:\/\/hivinfo.nih.gov\/understanding-hiv\/infographics\/fda-approval-hiv-medicines. Accessed 12 Jan 2022."},{"key":"1291_CR3","unstructured":"World Health Organization. HIV: from a devastating epidemic to a manageable chronic disease. WHO; 2017. https:\/\/www.who.int\/publications\/10-year-review\/chapter-hiv.pdf. Accessed 12 Jan 2022."},{"key":"1291_CR4","doi-asserted-by":"crossref","unstructured":"CANOC Collaboration, Patterson S, Cescon A, Samji H, Chan K, Zhang W, et al. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. BMC Infect Dis. 2015;15:274.","DOI":"10.1186\/s12879-015-0969-x"},{"key":"1291_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","volume":"372","author":"R Hogg","year":"2008","unstructured":"Hogg R. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293\u20139.","journal-title":"Lancet"},{"key":"1291_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081355","volume":"8","author":"H Samji","year":"2013","unstructured":"Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8: e81355.","journal-title":"PLoS ONE"},{"key":"1291_CR7","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1016\/S2352-3018(20)30358-1","volume":"8","author":"CL Smiley","year":"2021","unstructured":"Smiley CL, Rebeiro PF, Cesar C, Belaunzaran-Zamudio PF, Crabtree-Ramirez B, Padgett D, et al. Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study. Lancet HIV. 2021;8:e266\u201373.","journal-title":"Lancet HIV."},{"key":"1291_CR8","unstructured":"UNAIDS. 2020 Global AIDS update\u2014seizing the moment tackling entrenched inequalities to end epidemics. UNAIDS; 2020. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2020_global-aids-report_en.pdf. Accessed 12 Jan 2022."},{"key":"1291_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/QAI.0000000000001496","volume":"76","author":"A Calcagno","year":"2017","unstructured":"Calcagno A, Piconi S, Foc\u00e0 E, Nozza S, Carli F, Montrucchio C, et al. Role of normalized T-cell subsets in predicting comorbidities in a large cohort of geriatric HIV-infected patients. J Acquir Immune Defic Syndr. 2017;76:338\u201342.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1291_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11065-015-9305-x","volume":"25","author":"S DeVaughn","year":"2015","unstructured":"DeVaughn S, M\u00fcller-Oehring EM, Markey B, Bront\u00eb-Stewart HM, Schulte T. Aging with HIV-1 infection: motor functions, cognition, and attention\u2014a comparison with Parkinson\u2019s disease. Neuropsychol Rev. 2015;25:424\u201338.","journal-title":"Neuropsychol Rev"},{"key":"1291_CR11","doi-asserted-by":"crossref","unstructured":"Belaunzaran-Zamudio PF, Caro-Vega Y, Giganti MJ, Castilho JL, Crabtree-Ramirez BE, Shepherd BE, et al. Frequency of non-communicable diseases in people 50 years of age and older receiving HIV care in Latin America. Nunes BP, editor. PLoS One. 2020;15:e0233965.","DOI":"10.1371\/journal.pone.0233965"},{"key":"1291_CR12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.bjid.2012.11.007","volume":"17","author":"SW Cardoso","year":"2013","unstructured":"Cardoso SW, Torres TS, Santini-Oliveira M, Marins LMS, Veloso VG, Grinsztejn B. Aging with HIV: a practical review. Braz J Infect Dis. 2013;17:464\u201379.","journal-title":"Braz J Infect Dis"},{"issue":"12","key":"1291_CR13","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/17512433.2017.1377610","volume":"10","author":"A Chary","year":"2017","unstructured":"Chary A, Nguyen NN, Maiton K, Holodniy M. A review of drug\u2013drug interactions in older HIV-infected patients. Expert Rev Clin Pharmacol. 2017;10(12):1329\u201352.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1291_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1517\/17425255.2013.781153","volume":"9","author":"JC Schoen","year":"2013","unstructured":"Schoen JC, Erlandson KM, Anderson PL. Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin Drug Metab Toxicol. 2013;9:573\u201388.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1291_CR15","doi-asserted-by":"crossref","unstructured":"Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Intern AIDS Soc. 2020;23(2):e25449. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.25449. Accessed 31 Jan 2022.","DOI":"10.1002\/jia2.25449"},{"key":"1291_CR16","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/17512433.2017.1377610","volume":"10","author":"A Chary","year":"2017","unstructured":"Chary A, Nguyen NN, Maiton K, Holodniy M. A review of drug\u2013drug interactions in older HIV-infected patients. Expert Rev Clin Pharmacol. 2017;10:1329\u201352.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1291_CR17","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/cid\/cir627","volume":"53","author":"G Guaraldi","year":"2011","unstructured":"Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120\u20136.","journal-title":"Clin Infect Dis"},{"key":"1291_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40262-020-00916-9","volume":"60","author":"A Calcagno","year":"2020","unstructured":"Calcagno A, Molt\u00f3 J, Borghetti A, Gervasoni C, Milesi M, Valle M, et al. Older age is associated with higher dolutegravir exposure in plasma and cerebrospinal fluid of people living with HIV. Clin Pharmacokinet. 2020;60:103\u20139.","journal-title":"Clin Pharmacokinet"},{"key":"1291_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246171","volume":"16","author":"E Tyrberg","year":"2021","unstructured":"Tyrberg E, Ed\u00e9n A, Eriksen J, Nilsson S, Treutiger CJ, Thalme A, et al. Higher plasma drug levels in elderly people living with HIV treated with darunavir. PLoS ONE. 2021;16: e0246171.","journal-title":"PLoS ONE"},{"key":"1291_CR20","doi-asserted-by":"crossref","unstructured":"PRISMA-P Group, Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.","DOI":"10.1186\/2046-4053-4-1"},{"key":"1291_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/00325481.2018.1446653","volume":"130","author":"C Fontela","year":"2018","unstructured":"Fontela C, Castilla J, Juanbeltz R, Mart\u00ednez-Baz I, Rivero M, O\u2019Leary A, et al. Comorbidities and cardiovascular risk factors in an aged cohort of HIV-infected patients on antiretroviral treatment in a Spanish hospital in 2016. Postgrad Med. 2018;130:317\u201324.","journal-title":"Postgrad Med"},{"key":"1291_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ijid.2018.02.009","volume":"70","author":"RA Maciel","year":"2018","unstructured":"Maciel RA, Kl\u00fcck HM, Durand M, Sprinz E. Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: a cross-sectional study. Int J Infect Dis. 2018;70:30\u20135.","journal-title":"Int J Infect Dis"},{"key":"1291_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40262-018-0716-8","volume":"58","author":"A Daskapan","year":"2019","unstructured":"Daskapan A, Idrus LR, Postma MJ, Wilffert B, Kosterink JGW, Stienstra Y, et al. A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs. Clin Pharmacokinet. 2019;58:747\u201366.","journal-title":"Clin Pharmacokinet"},{"key":"1291_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3109\/23744235.2015.1034169","volume":"47","author":"L Calza","year":"2015","unstructured":"Calza L, Danese I, Colangeli V, Manfredi R, Magistrelli E, Verucchi G, et al. Plasma concentrations of efavirenz, darunavir\/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. Infect Dis (Lond). 2015;47:625\u201336.","journal-title":"Infect Dis (Lond)."},{"key":"1291_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1179\/1528433614Z.0000000006","volume":"16","author":"JH Vera","year":"2015","unstructured":"Vera JH, Jackson A, Dickinson L, Else L, Barber T, Mora-Peris B, et al. The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. HIV Clin Trials. 2015;16:39\u201342.","journal-title":"HIV Clin Trials"},{"issue":"12","key":"1291_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082672","volume":"8","author":"DH Johnson","year":"2013","unstructured":"Johnson DH, Sutherland D, Acosta EP, Erdem H, Richardson D, Haas DW. Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: A single arm pharmacokinetic study. PLoS ONE. 2013;8(12): e82672.","journal-title":"PLoS ONE"},{"key":"1291_CR27","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/jac\/dkv466","volume":"71","author":"D Cattaneo","year":"2016","unstructured":"Cattaneo D, Puoti M, Sollima S, Moioli C, Foppa CU, Baldelli S, et al. Reduced raltegravir clearance in HIV-infected liver transplant recipients: An unexpected interaction with immunosuppressive therapy? J Antimicrob Chemother. 2016;71:1341\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"1291_CR28","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.2217\/pgs.14.92","volume":"15","author":"A Calcagno","year":"2014","unstructured":"Calcagno A, Baietto L, Pagani N, Simiele M, Audagnotto S, D\u2019Avolio A, et al. Voriconazole and atazanavir: A CYP2C19-dependent manageable drug-drug interaction. Pharmacogenomics. 2014;15:1281\u20136.","journal-title":"Pharmacogenomics"},{"key":"1291_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.phrs.2011.09.006","volume":"65","author":"D Cattaneo","year":"2012","unstructured":"Cattaneo D, Gervasoni C, Cozzi V, Baldelli S, Fucile S, Meraviglia P, et al. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients. Pharmacol Res. 2012;65:198\u2013203.","journal-title":"Pharmacol Res"},{"key":"1291_CR30","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3851\/IMP2968","volume":"20","author":"ML Cottrell","year":"2015","unstructured":"Cottrell ML, Patterson KB, Prince HMA, Jones A, White N, Wang R, et al. Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract. Antiviral Ther. 2015;20:795\u2013803.","journal-title":"Antiviral Ther"},{"key":"1291_CR31","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/cid\/ciy201","volume":"67","author":"E Mogalian","year":"2018","unstructured":"Mogalian E, Stamm LM, Osinusi A, Brainard DM, Shen G, Ling KHJ, et al. Drug-Drug Interaction Studies between Hepatitis C Virus Antivirals Sofosbuvir\/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. Clin Infect Dis. 2018;67:934\u201340.","journal-title":"Clin Infect Dis"},{"key":"1291_CR32","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1097\/QAD.0b013e32835f2b49","volume":"27","author":"KB Patterson","year":"2013","unstructured":"Patterson KB, Prince HA, Stevens T, Shaheen NJ, Dellon ES, Madanick RD, et al. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS. 2013;27:1413\u20139.","journal-title":"AIDS"},{"key":"1291_CR33","doi-asserted-by":"crossref","unstructured":"Spinner CD, Wille F, Schwerdtfeger C, Thies P, Tanase U, Figura G, et al. Pharmacokinetics of chewed vs. swallowed raltegravir in a patient with AIDS and MAI infection: some new conflicting data. AIDS Res Ther. 2015;12(1):1.","DOI":"10.1186\/s12981-014-0041-8"},{"key":"1291_CR34","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/cid\/civ477","volume":"61","author":"A-M Taburet","year":"2015","unstructured":"Taburet A-M, Sauvageon H, Grinsztejn B, Assuied A, Veloso V, Pilotto JH, et al. Pharmacokinetics of raltegravir in HIV-infected patients on rifampicin-based antitubercular therapy. Clin Infect Dis. 2015;61:1328\u201335.","journal-title":"Clin Infect Dis"},{"key":"1291_CR35","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/jac\/dkt483","volume":"69","author":"M Weiner","year":"2014","unstructured":"Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69:1079\u201385.","journal-title":"J Antimicrob Chemother"},{"key":"1291_CR36","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1128\/AAC.00005-08","volume":"52","author":"LA Wenning","year":"2008","unstructured":"Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother. 2008;52:3253\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1291_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1365-2125.2008.03133.x","volume":"65","author":"S Abel","year":"2008","unstructured":"Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol. 2008;65:27\u201337.","journal-title":"Br J Clin Pharmacol"},{"key":"1291_CR38","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1128\/AAC.00292-13","volume":"57","author":"S Castellino","year":"2013","unstructured":"Castellino S, Moss L, Wagner D, Borland J, Song I, Chen S, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 2013;57:3536\u201346.","journal-title":"Antimicrob Agents Chemother"},{"key":"1291_CR39","first-page":"812","volume":"72","author":"M Merli","year":"2017","unstructured":"Merli M, Galli L, Marinaro L, Ariaudo A, Messina E, Uberti-Foppa C, et al. Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV\/hepatitis C virus-coinfected patients with liver cirrhosis. J Antimicrob Chemother. 2017;72:812\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"1291_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAI.0b013e31829ed7a4","volume":"64","author":"BN Greener","year":"2013","unstructured":"Greener BN, Patterson KB, Prince HMA, Sykes CS, Adams JL, Dumond JB, et al. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing. J Acquir Immune Defic Syndr. 2013;64:39\u201344.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1291_CR41","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/cpdd.996","volume":"10","author":"RP Singh","year":"2021","unstructured":"Singh RP, Adkison K, Wolstenholme A, Hopking J, Wynne B. Pharmacokinetics, safety, and tolerability of a single oral dose of abacavir\/dolutegravir\/lamivudine combination tablets in healthy Japanese study participants. Clin Pharmacol Drug Dev. 2021;10:985\u201393.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1291_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/QAD.0000000000002372","volume":"34","author":"P Courlet","year":"2019","unstructured":"Courlet P, Stader F, Guidi M, Alves Saldanha S, Stoeckle M, Cavassini M, et al. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. AIDS. 2019;34:103\u20138.","journal-title":"AIDS"},{"key":"1291_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3851\/IMP3355","volume":"25","author":"AL Blackman","year":"2020","unstructured":"Blackman AL, Heil EL, Devanathan AS, Pandit NS. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report. Antivir Ther. 2020;25:115\u20139.","journal-title":"Antivir Ther"},{"key":"1291_CR44","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1002\/phar.1960","volume":"37","author":"KM Brooks","year":"2017","unstructured":"Brooks KM, Garrett KL, Kuriakose SS, George JM, Balba G, Bailey B, et al. Decreased absorption of dolutegravir and tenofovir disoproxil fumarate, but not emtricitabine, in an HIV-infected patient following oral and jejunostomy-tube administration. Pharmacotherapy. 2017;37:e82\u20139.","journal-title":"Pharmacotherapy"},{"key":"1291_CR45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/QAI.0000000000001306","volume":"75","author":"JE Gallant","year":"2017","unstructured":"Gallant JE, Thompson M, DeJesus E, Voskuhl GW, Wei X, Zhang H, et al. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults. J Acquired Immune Defic Syndr. 2017;75:61\u20136.","journal-title":"J Acquired Immune Defic Syndr."},{"issue":"4","key":"1291_CR46","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/cpt.2178","volume":"109","author":"F Stader","year":"2021","unstructured":"Stader F, Courlet P, Decosterd LA, Battegay M, Marzolini C. Physiologically based pharmacokinetic modelling combined with Swiss HIV Cohort Study data supports no dose adjustment of bictegravir in elderly individuals living with HIV. Clin Pharmacol Ther. 2021;109(4):1025\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1291_CR47","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1093\/jac\/dkab319","volume":"76","author":"M Tempestilli","year":"2021","unstructured":"Tempestilli M, D\u2019Avolio A, De Nicol\u00f2 A, Agrati C, Antinori A, Cicalini S. Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV. J Antimicrob Chemother. 2021;76(12):3320\u20132.","journal-title":"J Antimicrob Chemother"},{"key":"1291_CR48","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/QAI.0000000000002765","volume":"88","author":"E Salama","year":"2021","unstructured":"Salama E, Hill L, Patel N, Best BM, Momper JD. Brief report: pharmacokinetics of bictegravir and tenofovir in combination with darunavir\/cobicistat in treatment-experienced persons with HIV. J Acquir Immune Defic Syndr. 2021;88:389\u201392.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1291_CR49","unstructured":"Hocqueloux L, Lefeuvre S, Bois J, Valentin C, Brucato S, Alix A, et al. Bioavailability of solid vs. dissolved vs. crushed single-tablet of bictegravir\/emtricitabine\/tenofovir alafenamide in HIV negative volunteers: the SOLUBIC study. HIV Med. 2021;22:132\u20133."},{"key":"1291_CR50","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","volume":"62","author":"K Agarwal","year":"2015","unstructured":"Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015;62:533\u201340.","journal-title":"J Hepatol"},{"key":"1291_CR51","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.1128\/AAC.00005-16","volume":"60","author":"JM Custodio","year":"2016","unstructured":"Custodio JM, Fordyce M, Garner W, Vimal M, Ling KHJ, Kearney BP, et al. Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment. Antimicrob Agents Chemother. 2016;60:5135\u201340.","journal-title":"Antimicrob Agents Chemother"},{"key":"1291_CR52","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/QAI.0000000000001699","volume":"78","author":"R Begley","year":"2018","unstructured":"Begley R, Das M, Zhong L, Ling J, Kearney BP, Custodio JM. Pharmacokinetics of tenofovir alafenamide when coadministered with other hiv antiretrovirals. J Acquired Immune Defic Syndr. 2018;78:465\u201372.","journal-title":"J Acquired Immune Defic Syndr."},{"key":"1291_CR53","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1310\/hct1403-92","volume":"14","author":"G Di Perri","year":"2013","unstructured":"Di Perri G, Green B, Morrish G, Hill A, Faetkenheuer G, Bickel M, et al. Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-na\u00efve patients. HIV Clin Trials. 2013;14:92\u20138.","journal-title":"HIV Clin Trials"},{"key":"1291_CR54","volume":"2012","author":"T Kakuda","year":"2012","unstructured":"Kakuda T, Sekar V, Vis P, Coate B, Ryan R, Anderson D, et al. Pharmacokinetics and pharmacodynamics of darunavir and etravirine in HIV-1-infected, treatment-experienced patients in the gender, race, and clinical experience (GRACE) trial. AIDS Res Treat. 2012;2012: 186987.","journal-title":"AIDS Res Treat."},{"key":"1291_CR55","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/FTD.0000000000000200","volume":"37","author":"A Calcagno","year":"2015","unstructured":"Calcagno A, Trentalange A, Simiele M, Marinaro L, Patti F, Tettoni MC, et al. Rilpivirine pharmacokinetics in 3 HIV-positive patients with liver cirrhosis concomitantly receiving pantoprazole. Ther Drug Monit. 2015;37:695\u20136.","journal-title":"Ther Drug Monit"},{"key":"1291_CR56","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/jac\/dku575","volume":"70","author":"M Lamorde","year":"2014","unstructured":"Lamorde M, Walimbwa S, Byakika-Kibwika P, Katwere M, Mukisa L, Sempa JB, et al. Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. J Antimicrob Chemother. 2014;70:1482\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"1291_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.353","volume":"5","author":"JM Custodio","year":"2017","unstructured":"Custodio JM, Chuck SK, Chu H, Cao H, Ma G, Flaherty J, et al. Lack of clinically important PK interaction between coformulated ledipasvir\/sofosbuvir and rilpivirine\/emtricitabine\/tenofovir alafenamide. Pharmacol Res Perspect. 2017;5(5): e00353.","journal-title":"Pharmacol Res Perspect"},{"key":"1291_CR58","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1128\/AAC.01441-15","volume":"59","author":"L Dickinson","year":"2015","unstructured":"Dickinson L, Yapa HM, Jackson A, Moyle G, Else L, Amara A, et al. Plasma tenofovir, emtricitabine, and rilpivirine and intracellular tenofovir diphosphate and emtricitabine triphosphate pharmacokinetics following drug intake cessation. Antimicrob Agents Chemother. 2015;59:6080\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"1291_CR59","first-page":"100","volume":"4","author":"A Mathias","year":"2012","unstructured":"Mathias A, Menning M, Wiser L, Wei X, Dave A, Chuck S, et al. Bioequivalence of the emtricitabine\/rilpivirine\/tenofovir disoproxil fumarate single tablet regimen. J Bioequivalence Bioavailab. 2012;4:100\u20135.","journal-title":"J Bioequivalence Bioavailab."},{"issue":"8","key":"1291_CR60","doi-asserted-by":"publisher","first-page":"e00326","DOI":"10.1128\/AAC.00326-18","volume":"62","author":"W Ankrom","year":"2018","unstructured":"Ankrom W, Yee KL, Sanchez RI, Adedoyin A, Fan L, Marbury T, et al. Severe renal impairment has minimal impact on doravirine pharmacokinetics. Antimicrob Agents Chemother. 2018;62(8):e00326-e418.","journal-title":"Antimicrob Agents Chemother"},{"key":"1291_CR61","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3851\/IMP3142","volume":"22","author":"MO Behm","year":"2017","unstructured":"Behm MO, Yee KL, Fan L, Fackler P. Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects. Antiviral Ther. 2017;22:337\u201344.","journal-title":"Antiviral Ther"},{"key":"1291_CR62","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3851\/IMP2920","volume":"20","author":"MS Anderson","year":"2015","unstructured":"Anderson MS, Gilmartin J, Cilissen C, De Lepeleire I, Van Bortel L, Dockendorf MF, et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antiviral Ther. 2015;20:397\u2013405.","journal-title":"Antiviral Ther"},{"key":"1291_CR63","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/hiv.12478","volume":"18","author":"L Calza","year":"2017","unstructured":"Calza L, Colangeli V, Magistrelli E, Bussini L, Conti M, Ramazzotti E, et al. Plasma trough concentrations of darunavir\/ritonavir and raltegravir in older patients with HIV-1 infection. HIV Med. 2017;18:474\u201381.","journal-title":"HIV Med"},{"key":"1291_CR64","doi-asserted-by":"publisher","first-page":"805","DOI":"10.5414\/CP202066","volume":"52","author":"TN Kakuda","year":"2014","unstructured":"Kakuda TN, Leopold L, Timmers M, Van De Casteele T, Hillewaert V, Tomaka FL, et al. Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation. Int J Clin Pharmacol Ther. 2014;52:805\u201316.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1291_CR65","doi-asserted-by":"crossref","unstructured":"Cojutti PG, Londero A, Della Siega P, Givone F, Fabris M, Biasizzo J, et al. Comparative population pharmacokinetics of darunavir in SARS-CoV-2 patients vs. HIV patients: the role of interleukin-6. Clin Pharmacokinet. 2020;59:1251\u201360.","DOI":"10.1007\/s40262-020-00933-8"},{"key":"1291_CR66","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/jac\/dks486","volume":"68","author":"NE Dufty","year":"2013","unstructured":"Dufty NE, Gilleran G, Hawkins D, Else LJ, Taylor S. Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma. J Antimicrob Chemother. 2013;68:972\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"1291_CR67","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1310\/hct1403-99","volume":"14","author":"M Vourvahis","year":"2013","unstructured":"Vourvahis M, Fang J, Checchio T, Milton A, Weatherley B, McFadyen L, et al. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function. HIV Clin Trials. 2013;14:99\u2013109.","journal-title":"HIV Clin Trials"},{"key":"1291_CR68","unstructured":"World Health Organization (WHO). WHO recommends dolutegravir as preferred HIV treatment option in all populations. 2019. https:\/\/www.who.int\/news\/item\/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations#:~:text=Based%20on%20new%20evidence%20assessing,and%20those%20of%20childbearing%20potential. Accessed 4 Nov 2022."},{"key":"1291_CR69","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciy426","volume":"68","author":"ER Elliot","year":"2019","unstructured":"Elliot ER, Wang X, Singh S, Simmons B, Vera JH, Miller RF, et al. Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition. Clin Infect Dis. 2019;68:87\u201395.","journal-title":"Clin Infect Dis"},{"key":"1291_CR70","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/bcp.12639","volume":"80","author":"J Zhang","year":"2015","unstructured":"Zhang J, Hayes S, Sadler BM, Minto I, Brandt J, Piscitelli S, et al. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. Br J Clin Pharmacol. 2015;80:502\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"1291_CR71","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/17425255.2021.1915285","volume":"17","author":"A Calcagno","year":"2021","unstructured":"Calcagno A, Trunfio M, D\u2019Avolio A, Di Perri G, Bonora S. The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV. Expert Opin Drug Metab Toxicol. 2021;17:665\u201376.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1291_CR72","unstructured":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/what-start-initial-combination-regimens?view=full."},{"key":"1291_CR73","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1089\/aid.2009.0154","volume":"26","author":"KW Crawford","year":"2010","unstructured":"Crawford KW, Spritzler J, Kalayjian RC, Parsons T, Landay A, Pollard R, et al. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses. 2010;26:635\u201343.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"1291_CR74","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/bcp.14402","volume":"87","author":"F Stader","year":"2020","unstructured":"Stader F, Courlet P, Kinvig H, Battegay M, Decosterd LA, Penny MA, et al. Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. Br J Clin Pharmacol. 2020;87(2):458\u201370.","journal-title":"Br J Clin Pharmacol"},{"key":"1291_CR75","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1128\/AAC.00487-08","volume":"52","author":"MS Anderson","year":"2008","unstructured":"Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother. 2008;52:4228\u201332.","journal-title":"Antimicrob Agents Chemother"},{"key":"1291_CR76","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1128\/AAC.00789-10","volume":"55","author":"J Molt\u00f3","year":"2011","unstructured":"Molt\u00f3 J, Valle M, Back D, Cede\u00f1o S, Watson V, Liptrott N, et al. Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients. Antimicrob Agents Chemother. 2011;55:72\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"1291_CR77","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40261-014-0198-x","volume":"34","author":"CY Yu","year":"2014","unstructured":"Yu CY, Campbell SE, Sponseller CA, Small DS, Medlock MM, Morgan RE. Steady-state pharmacokinetics of darunavir\/ritonavir and pitavastatin when co-administered to healthy adult volunteers. Clin Drug Invest. 2014;34:475\u201382.","journal-title":"Clin Drug Invest"},{"key":"1291_CR78","doi-asserted-by":"publisher","first-page":"232595822091923","DOI":"10.1177\/2325958220919231","volume":"19","author":"C Wassner","year":"2020","unstructured":"Wassner C, Bradley N, Lee Y. A review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide. J Int Assoc Provid AIDS Care. 2020;19:2325958220919231.","journal-title":"J Int Assoc Provid AIDS Care."},{"key":"1291_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105812","volume":"162","author":"Z Vinarov","year":"2021","unstructured":"Vinarov Z, Abdallah M, Agundez JAG, Allegaert K, Basit AW, Braeckmans M, et al. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: an UNGAP review. Eur J Pharm Sci. 2021;162: 105812.","journal-title":"Eur J Pharm Sci"},{"key":"1291_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105280","volume":"147","author":"C Stillhart","year":"2020","unstructured":"Stillhart C, Vu\u010di\u0107evi\u0107 K, Augustijns P, Basit AW, Batchelor H, Flanagan TR, et al. Impact of gastrointestinal physiology on drug absorption in special populations\u2013\u2013an UNGAP review. Eur J Pharm Sci. 2020;147: 105280.","journal-title":"Eur J Pharm Sci"},{"key":"1291_CR81","unstructured":"US FDA. BIKTARVY: Highlights of prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210251s000lbl.pdf. Accessed 26 Jan 2021."},{"key":"1291_CR82","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/jcpt.12755","volume":"43","author":"C Cimino","year":"2018","unstructured":"Cimino C, Binkley A, Swisher R, Short WR. Antiretroviral considerations in HIV-infected patients undergoing bariatric surgery. J Clin Pharm Ther. 2018;43:757\u201367.","journal-title":"J Clin Pharm Ther"},{"key":"1291_CR83","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s40265-018-1010-7","volume":"78","author":"ED Deeks","year":"2018","unstructured":"Deeks ED. Bictegravir\/emtricitabine\/tenofovir alafenamide: a review in HIV-1 infection. Drugs. 2018;78:1817\u201328.","journal-title":"Drugs"},{"key":"1291_CR84","doi-asserted-by":"publisher","first-page":"5447","DOI":"10.2147\/DDDT.S90580","volume":"2","author":"G Kanmogne","year":"2015","unstructured":"Kanmogne G, Woollard S. Maraviroc: a review of its use in HIV infection and beyond. Drug Des Dev Ther. 2015;2:5447.","journal-title":"Drug Des Dev Ther."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01291-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01291-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01291-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T08:35:35Z","timestamp":1692866135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01291-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":84,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1291"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01291-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"assertion":[{"value":"20 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior-CAPES-Finance Code 001, and by the Carlos Chagas Filho Foundation for Research Support in the State of Rio de Janeiro (FAPERJ) [E-26\/010.101.009\/2018]. BG and TST were funded by the National Council of Technological and Scientific Development (CNPq) and FAPERJ.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Thain\u00e1 Toledo, Thales Castro, Vanessa G. Oliveira, Valdilea Gon\u00e7alves Veloso, Beatriz Grinsztejn, Sandra Wagner Cardoso, Thiago S. Torres, and Rita Estrela declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"RE and TST conceived the study. The literature search and data analysis were performed by TT, RE, TST, TC, and VGO. TT drafted the manuscript and RE, TST, TC, VGO, SWC, VGV and BG critically revised the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}